County-Level Variation in Substance Use Disorder Service Utilization by Insurance Payers and Self-Pay in the United States
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 25 of the 48 sources its claims cite were checked for support.
Abstract
Objectives: To examine county-level variations in and correlates of substance use disorders (SUD) health service utilization by insurance payers (Medicaid, private insurance, and Medicare) and self-pay. Methods: We extracted service utilization for SUDs from the Disease Expenditure 2017-2019 Project... Results: During 2017-2019, Medicaid (52.7%) and private insurance (32.3%) financed 85.0% of annual average SUD service expenditures examined, accounting for 50.6% of SUD service utilizations. Across 3143 counties, the average annual county-level number of SUD service utilizations was 5.2 per 1000 county residents. Self-pay individuals had the highest average county-level number of SUD service utilizations (8.6 per 1000 county residents), followed by Medicaid beneficiaries (6.9 per 1000) and private insurance (2.8 per 1000). County-level percentage of uninsured adults was negatively associated with SUD service utilization overall (standardized β=-0.45, P<.0001), accounting for 23.0% of its variance. Across all examined payers, Medicaid funded a disproportionate share—over 50%—of SUD service expenditures.
Overview
CoChat Summary
TL;DR
This study examined county-level variation in substance use disorder (SUD) service utilization by payer and self-pay across 3,143 U.S. counties during 2017–2019. It found that Medicaid and private insurance financed 85.0% of examined SUD service expenditures, while county-level uninsured adult percentage was the strongest negative correlate of SUD service utilization.
Key findings
- Annual average SUD service expenditures across examined payers were $31 billion during 2017–2019; Medicaid paid 52.7% of SUD service expenditures despite accounting for 18.4% of overall healthcare expenditures, and private insurance paid 32.3%.
- Medicaid and private insurance together financed 85.0% of SUD service expenditures and accounted for 50.6% of SUD service utilizations; self-pay accounted for 5.1% of SUD service expenditures but 43.0% of SUD service utilizations.
- Across 3,143 counties, average annual SUD service utilization was 5.2 per 1,000 county residents (95% CI=5.1–5.3); self-pay had the highest average county-level utilization (8.6, 95% CI=8.4–8.6), followed by Medicaid (6.9, 95% CI=6.6–7.1 per 1,000 Medicaid enrollees) and private insurance (2.8, 95% CI=2.7–2.8 per 1,000 privately insured residents).
- County-level percentage of uninsured adults was negatively associated with overall SUD service utilization (standardized β=−0.45, highest across examined variables, P<.0001) and accounted for 23.0% of its variance; SUD-related healthcare resource indicators explained an additional 2.3%.
Methods
- Extracted county-level SUD service utilization by payer from the Disease Expenditure 2017–2019 Project, defining utilization as healthcare encounters, visits, admissions, or prescriptions for SUDs (alcohol or drug use disorders, excluding tobacco).
- Linked county-level data using FIPS codes to 2017–2019 model-based drug overdose mortality data, 2018–2022 County Health Rankings, 2021 Area Health Resources Files, and 2016–2021 Opioid Environment Policy Scan data.
- Conducted descriptive analyses, t-tests with Bonferroni adjustments comparing bottom vs. top 20% counties, simple linear regressions, and sequential regression/generalized linear models examining county-level correlates of SUD service utilization by payer.
Limitations
- The paper states it could not adjust for county-level SUD prevalence due to data unavailability and compared counties by SUD service use, not SUD prevalence.
- The paper states analyses used county-level rather than individual-level data, so cautious interpretation is warranted to avoid ecological fallacy; mortality data also lacked overdose decedents’ insurance or employment status.
- The paper states it could not examine other payers, such as the Substance Abuse Prevention and Treatment Block Grant, and notes future research should examine trends with more recent data; the cross-sectional 2017–2019 design also limits causal inference (evident from the text).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 2 Not valid · 8 Not checked · 61 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, out-of-pocket payments for SUD treatment are common,16-17 although the extent is largely unknown.”
§ County-level variation in substance use disorder service utilization by insurance payers and self-pay in the United States > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites [16] Watema-Lord R, Xie F, Sanyal C. The effect of out-of-pocket costs on medications for opioid use disorder and overdose: A scoping review. J Am Pharm Assoc. 2025; 65(1): 102299. doi: 10.1016/j.japh.2024.102299 39631630 source
- Partly supportedcites [17] Strahan AE, Desai S, Zhang K, Guy GP Jr. Trends in out-of-pocket costs for and characteristics of pharmacy-dispensed buprenorphine medications for opioid use disorder treatment by type of payer, 2015 to 2020. JAMA Netw Open. 2023; 6(2): e2254590. Published 2023 Feb 1. doi: 10.1001/jamanetworkopen.2022.54590 36763363 PMC9918874 sourceExperimental — accuracy not yet measured
The Discussion reports out-of-pocket costs across payer types for pharmacy-dispensed buprenorphine prescriptions, and the Results report substantial numbers of self-pay and assistance-paid prescriptions. This supports the claim for one form of opioid use disorder treatment, but the paper does not establish how common out-of-pocket payments are across substance use disorder treatments generally. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Across all examined payers, self-payment was associated with the lowest number of days supplied for buprenorphine prescriptions.17”
§ County-level variation in substance use disorder service utilization by insurance payers and self-pay in the United States > DISCUSSION
What the sources say
- Supportedcites [17] Strahan AE, Desai S, Zhang K, Guy GP Jr. Trends in out-of-pocket costs for and characteristics of pharmacy-dispensed buprenorphine medications for opioid use disorder treatment by type of payer, 2015 to 2020. JAMA Netw Open. 2023; 6(2): e2254590. Published 2023 Feb 1. doi: 10.1001/jamanetworkopen.2022.54590 36763363 PMC9918874 source
The Results report that, among buprenorphine prescriptions dispensed in 2020, self-pay had the shortest mean days’ supply of the payer categories examined: 12.62 days. This supports the claim as a comparison across payers, though the reported comparison is specifically for 2020. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A one-dollar increase in daily out-of-pocket buprenorphine cost was associated with a 12-14% decrease in retention.27”
§ County-level variation in substance use disorder service utilization by insurance payers and self-pay in the United States > DISCUSSION
What the sources say
- Partly supportedcites [27] Dunphy C, Peterson C, Zhang K, Jones CM. Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder? Drug Alcohol Depend. 2021; 225: 108784. doi: 10.1016/j.drugalcdep.2021.108784 34049104 PMC8314254 sourceExperimental — accuracy not yet measured
The Results report that a $1 increase in average daily out-of-pocket buprenorphine cost was associated with 12%, 14%, and 13% lower odds of retention at 180, 360, and 540 days, respectively. The cited sentence gives the correct range but says retention decreased by 12–14%, rather than the odds of retention. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Since 2017, Medicaid fee-for-service benefits have increased coverage for SUD treatment services and medications.40”
§ County-level variation in substance use disorder service utilization by insurance payers and self-pay in the United States > DISCUSSION
What the sources say
- Supportedcites [40] Shoulders A, Andrews CM, Westlake MA, Abraham AJ, Grogan CM. Changes in Medicaid fee-for-service benefit design for substance use disorder treatment during the opioid crisis, 2014 to 2021. JAMA Health Forum. 2023; 4(8): e232502. Published 2023 Aug 4. doi: 10.1001/jamahealthforum.2023.2502 37566428 PMC10422193 source
The Discussion says Medicaid fee-for-service benefits for SUD treatment continued to improve since 2017 and that coverage for treatment and OUD medications increased. The Results (Benefit Coverage) report increases in coverage for treatment services and OUD medications through 2021; the medications studied were specifically for OUD. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, utilization management strategies are commonly used in Medicaid and private insurance plans to regulate SUD treatment benefits through mechanisms such as prior authorization, drug testing, annual maximums, duration restrictions, high deductibles, and monthly caps on total prescriptions,24, 26, 34-35”
§ County-level variation in substance use disorder service utilization by insurance payers and self-pay in the United States > DISCUSSION
What the sources say
- Partly supportedcites [24] Bowser D, Bohler R, Davis MT, Hodgkin D, Horgan C. Payment-related barriers to medications for opioid use disorder: A critical review of the literature and real-world application. J Subst Use Addict Treat. 2024; 165: 209441. doi: 10.1016/j.josat.2024.209441 38906417 PMC11463342 sourceExperimental — accuracy not yet measured
The Introduction identifies prior authorization as a health-plan utilization-management technique, and Results > Patient perspective describes duration restrictions and Medicaid monthly prescription caps. Discussion > Impact on patients also discusses high deductibles as a cost barrier. The cited passages do not establish drug testing or annual maximums as mechanisms, or classify high deductibles as utilization management; the paper addresses MOUD specifically rather than SUD treatment benefits generally. (LLM, conf=0.86)
- Partly supportedcites [26] Morgan JR, Quinn EK, Chaisson CE, Variation in initiation, engagement, and retention on medications for opioid use disorder based on health insurance plan design. Med Care. 2022; 60(3): 256– 263. doi: 10.1097/MLR.0000000000001689 35026792 PMC8852217 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [34] Peterson LA, Andrews CM, Abraham AJ, Westlake MA, Grogan CM. Most states allow Medicaid managed care plans discretion to restrict substance use disorder treatment benefits. Health Aff (Millwood). 2024; 43(7): 1038– 1046. doi: 10.1377/hlthaff.2023.01023 38950296 source
- Partly supportedcites [35] McGinty EE, White SA, Eisenberg MD, Palmer NR, Brown CH, Saloner BK. US payment policy for medications to treat opioid use disorder: landscape and opportunities. Health Aff Sch. 2024; 2(3): qxae024. Published 2024 Feb 27. doi: 10.1093/haschl/qxae024 38756918 PMC10986242 sourceExperimental — accuracy not yet measured
Our copy supports only part of the enumerated mechanisms: the Insurance Restrictions/Table sections state that 'Medicare Advantage, Medicaid, and private insurance all use deductible, copayment, coinsurance, and prior authorization requirements for office-based and OTP-based MOUD,' and the Introduction flags 'high cost-sharing and prior authorization requirements' as insurance barriers. However, the paper is scoped to medications for opioid use disorder (MOUD) payment policy, not SUD treatment benefits generally, and it never mentions drug testing, annual maximums, duration restrictions, or monthly caps on total prescriptions; the closest it comes is the Discussion remark that 'other less common insurance restrictions, such as quantity limits, remain in place,' which is framed as less common rather than a commonly used mechanism. The citing sentence's broad 'utilization management strategies... to regulate SUD treatment benefits' list therefore overstates what this source reports. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
55 more claims · 2 with their cited sources checked
Create a free account to see all 85 claims and to verify the 7 references still open.
- Probably not a substantial claim. 19
- It may state two separate claims as one. 14
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ County-level variation in substance use disorder service utilization by insurance payers and self-pay in the United States > RESULTS > Variation in SUD health service utilizations across US counties, by payer
“those with self-pay had the highest average annual county-level number of SUD health service utilizations (8.6, 95% CI=8.4-8.6 per 1000 county residents)”
§ County-level variation in substance use disorder service utilization by insurance payers and self-pay in the United States > RESULTS > Variation in SUD health service utilizations across US counties, by payer
“the average annual county-level number of SUD health service utilizations from examined payers was 5.2 (95% CI=5.1-5.3) per 1000 county residents”
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Research works printed but not linked: 2
- [1]National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder. Medications for Opioid Use Disorder Save Lives. Mancher M, Leshner AI, editors. Washington (DC): National Academies Press (US); 2019 Mar 30. 30896911
- [13]Han B, Volkow ND, Jones CM, Polysubstance use disorders among US adults. Manuscript under journal review.
Metadata
- Authors
- Han, B., Compton, W. M., Jones, C. M., Stimson, D. T., Barfield, E. T., Bellgowan, J. F., Hobin, J. A., & Volkow, N. D.
- Affiliations
- National Institutes of Health (US)
- Substance Abuse and Mental Health Services Administration (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2026-06-08
- Volume
- 87
- Issue
- 3
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- PMC
- PMC13352591
- OpenAlex
- W7163806377
- Cited by
- 0
- References
- 0
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- substance use disorders, health care utilization, county-level variation, Medicaid, private insurance, Medicare, self-pay, uninsured rate, health insurance coverage, opioid overdose deaths, access to addiction treatment
- MeSH terms
- Health Expenditures, Female, Medicare, Humans, Insurance, Health, Medicaid, Patient Acceptance of Health Care, United States, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.